Share This Page
Drug Price Trends for NDC 00904-6500
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-6500
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FLUCONAZOLE 100 MG TABLET | 00904-6500-61 | 0.23483 | EACH | 2026-03-18 |
| FLUCONAZOLE 100 MG TABLET | 00904-6500-06 | 0.23483 | EACH | 2026-03-18 |
| FLUCONAZOLE 100 MG TABLET | 00904-6500-61 | 0.22991 | EACH | 2026-02-18 |
| FLUCONAZOLE 100 MG TABLET | 00904-6500-06 | 0.22991 | EACH | 2026-02-18 |
| FLUCONAZOLE 100 MG TABLET | 00904-6500-61 | 0.23998 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-6500
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novartis's Indication Expansion for Kisqali: Market Dynamics and Price Outlook
Novartis AG’s Kisqali (ribociclib) is demonstrating significant market traction following its expanded indication for metastatic breast cancer (MBC) in combination with endocrine therapy in postmenopausal women and men. The drug's enhanced efficacy data, particularly in the MONALEESA-7 trial and subsequent real-world evidence, supports its position as a front-line therapy. This analysis projects market potential and price trajectory for Kisqali, assessing its competitive landscape and future revenue generation.
What is the Current Market Position of Kisqali?
Kisqali, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is marketed by Novartis. Its primary indication is for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. The drug is typically administered in combination with an aromatase inhibitor or fulvestrant.
Key Market Data:
- Global Sales (2023): $5.46 billion [1].
- Year-over-Year Growth (2023): 46% [1].
- Target Patient Population: Primarily women and men with HR+/HER2- advanced or metastatic breast cancer.
- Competitive Landscape: Competes with other CDK4/6 inhibitors, including Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).
The market for CDK4/6 inhibitors has grown substantially due to demonstrated improvements in progression-free survival (PFS) and overall survival (OS) when used in combination therapies for HR+/HER2- metastatic breast cancer. Kisqali’s performance in clinical trials, particularly the significant improvement in OS observed in the MONALEESA-7 trial, has solidified its position as a preferred first-line treatment option [2].
What are the Approved Indications and Evolving Treatment Pathways?
Kisqali has secured approvals for multiple indications, broadening its therapeutic reach.
Approved Indications:
- Initial Approval (2017): In combination with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, following prior endocrine therapy [3].
- Expanded Approval (2018): In combination with fulvestrant for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, as initial endocrine therapy or following disease progression after prior endocrine therapy [3].
- Expanded Approval (2022): In combination with an aromatase inhibitor for men with HR+/HER2- advanced or metastatic breast cancer, as initial endocrine therapy [4].
- Expanded Approval (2023): In combination with endocrine therapy (fulvestrant or an aromatase inhibitor) for adult patients with HR+/HER2- advanced or metastatic breast cancer, as initial endocrine therapy or following disease progression after prior endocrine therapy [5]. This broadens the initial and extended indications to encompass both sexes and all lines of endocrine-based therapy for advanced/metastatic HR+/HER2- breast cancer.
The recent broad label expansion for Kisqali in combination with endocrine therapy has significantly expanded its addressable market. This allows for its use across various endocrine therapy backbones and lines of treatment in advanced or metastatic HR+/HER2- breast cancer, aiming to delay disease progression and improve survival outcomes [5].
What is the Efficacy and Safety Profile of Kisqali?
Kisqali's clinical profile is characterized by its ability to inhibit CDK4 and CDK6, enzymes that promote cell cycle progression. This inhibition, when combined with endocrine therapy, leads to improved anti-tumor activity.
Key Efficacy Data:
- MONALEESA-2 (First-line, AI + Kisqali): Median OS of 63.0 months vs. 50.9 months (placebo) [6]. Median PFS of 27.1 months vs. 14.7 months (placebo) [6].
- MONALEESA-7 (First-line, pre- or perimenopausal women, AI + Kisqali): Median OS of 58.7 months vs. 48.2 months (placebo) [7]. Median PFS of 22.1 months vs. 11.4 months (placebo) [7].
- MONALEESA-3 (First- or second-line, Fulvestrant + Kisqali): Median OS of 53.7 months vs. 41.5 months (placebo) [8]. Median PFS of 11.3 months vs. 7.0 months (placebo) [8].
Common Adverse Events (AEs) requiring dose interruption or reduction:
- Neutropenia
- Diarrhea
- Fatigue
- Nausea
- Hepatotoxicity
The safety profile is generally manageable with dose adjustments and supportive care. Neutropenia is the most frequent dose-limiting toxicity, requiring regular monitoring of blood counts [1, 6, 7, 8].
What are the Key Market Drivers and Restraints?
The market growth for Kisqali is influenced by several factors.
Market Drivers:
- Expanding Indications: Broadened label approvals increase the eligible patient population.
- Improved Survival Outcomes: Robust clinical trial data demonstrating significant OS and PFS benefits [1, 6, 7, 8].
- Durable Responses: Kisqali has shown the potential for long-term disease control in a subset of patients.
- Growing Awareness: Increased physician and patient awareness of the benefits of CDK4/6 inhibitors.
- Combination Therapy Paradigm: The established use of CDK4/6 inhibitors as a standard of care in combination regimens.
Market Restraints:
- Competition: Presence of other CDK4/6 inhibitors (Ibrance, Verzenio) and emerging therapies.
- Cost of Treatment: High acquisition cost can limit access and create payer challenges.
- Adverse Event Management: Management of toxicities, particularly neutropenia and diarrhea, can impact patient adherence and physician prescribing patterns.
- Patent Expirations: Future generic competition will impact long-term revenue.
What is the Competitive Landscape for CDK4/6 Inhibitors?
The CDK4/6 inhibitor market is a competitive space with three major players.
| Drug Name | Manufacturer | Mechanism of Action | Primary Indications | 2023 Net Sales |
|---|---|---|---|---|
| Kisqali (ribociclib) | Novartis AG | CDK4/6 Inhibitor | HR+/HER2- advanced or metastatic breast cancer in combination with endocrine therapy. | $5.46 billion |
| Ibrance (palbociclib) | Pfizer Inc. | CDK4/6 Inhibitor | HR+/HER2- advanced or metastatic breast cancer in combination with endocrine therapy. | $5.15 billion |
| Verzenio (abemaciclib) | Eli Lilly and Company | CDK4/6 Inhibitor | HR+/HER2- advanced or metastatic breast cancer, as monotherapy or in combination with endocrine therapy or fulvestrant. | $4.18 billion |
Note: Sales figures are approximate and may vary based on reporting periods and currency exchange rates. Verzenio also has indications for early-stage breast cancer.
Verzenio has demonstrated a broader clinical profile, including approvals in the adjuvant setting for high-risk early breast cancer, which differentiates it from Kisqali and Ibrance. Novartis is actively investigating Kisqali in earlier lines of therapy and potentially in other cancer types.
What are the Price Projections and Revenue Outlook for Kisqali?
Kisqali’s pricing strategy reflects its clinical value and the competitive market. The drug is positioned as a premium-priced therapy, aligning with the significant benefits it offers in improving patient outcomes.
Pricing Factors:
- Clinical Value: Demonstrated improvements in OS and PFS translate to higher perceived value.
- Competitive Pricing: Prices are benchmarked against existing CDK4/6 inhibitors.
- Payer Negotiations: Reimbursement rates and formulary placement are critical.
- Dosing and Regimen: The standard dosing regimen influences cost per treatment cycle.
Estimated Annual Treatment Cost (United States, as of late 2023/early 2024):
- Kisqali (ribociclib) typically costs between $10,000 to $12,000 per month before discounts and rebates [9]. This translates to an annual cost of approximately $120,000 to $144,000 per patient.
Revenue Outlook:
Given the expanded indication, strong clinical data, and the continued demand for effective HR+/HER2- metastatic breast cancer therapies, Kisqali is projected to maintain significant revenue growth.
- Mid-Term Growth (2024-2026): Expect continued strong double-digit growth, driven by the expanded label and market penetration in first-line and subsequent lines of therapy. Annual sales are projected to exceed $7 billion by 2025.
- Long-Term Outlook (Post-2027): Revenue growth will likely moderate as patent expirations approach and generic competition emerges. However, potential for new indications or combination strategies could sustain revenue. Projections indicate potential to reach $8-9 billion annually before significant generic erosion.
The continued success will depend on Novartis's ability to navigate payer landscapes, manage the drug's safety profile in broader patient populations, and potentially secure further approvals.
What are the Patent Expirations and Generic Implications?
The patent landscape for Kisqali is crucial for understanding its long-term revenue sustainability. While specific patent expiry dates can vary by region and are subject to legal challenges, the primary patents protecting Kisqali are expected to expire in the mid-to-late 2020s.
- Core Patents: Compound patents are generally set to expire around 2027-2029 in major markets like the U.S. and Europe.
- Formulation and Method-of-Use Patents: Novartis holds additional patents related to specific formulations and methods of use, which may extend exclusivity in certain contexts.
- Generic Entry: Following patent expiry, generic versions of ribociclib are likely to enter the market, significantly reducing the price and impacting Novartis's market share and revenue. Generic pricing is typically 70-90% lower than branded drug prices.
The exact timing and impact of generic entry will depend on regulatory approvals and patent litigation outcomes. However, companies must anticipate a substantial decline in Kisqali’s revenue post-patent expiry.
Key Takeaways
- Novartis’s Kisqali is a leading CDK4/6 inhibitor with a strong market position, achieving $5.46 billion in 2023 sales.
- The drug’s expanded indication for HR+/HER2- advanced or metastatic breast cancer, combined with endocrine therapy, broadens its addressable market significantly.
- Robust clinical data, particularly demonstrating improvements in overall survival, underpins Kisqali’s efficacy and market demand.
- The competitive landscape includes Pfizer’s Ibrance and Eli Lilly’s Verzenio, with Verzenio holding an advantage in early-stage breast cancer indications.
- Annual treatment costs for Kisqali are substantial, ranging from $120,000 to $144,000 per patient in the U.S.
- Kisqali is projected to exceed $7 billion in annual sales by 2025, with potential to reach $8-9 billion before significant generic erosion.
- Primary patents are expected to expire between 2027 and 2029, paving the way for generic competition and subsequent revenue decline.
Frequently Asked Questions
-
What is the primary mechanism of action for Kisqali? Kisqali is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in cell cycle progression, and their inhibition in combination with endocrine therapy aims to halt the growth of HR+/HER2- breast cancer cells.
-
How does Kisqali compare to Verzenio in terms of approved indications? Kisqali is approved for HR+/HER2- advanced or metastatic breast cancer in combination with endocrine therapy for both men and postmenopausal women. Verzenio has a similar indication but also holds approvals for HR+/HER2- early breast cancer (adjuvant setting), offering a broader range of treatment options.
-
What are the most common side effects associated with Kisqali treatment? The most frequently observed side effects that may lead to dose interruption or reduction include neutropenia, diarrhea, fatigue, nausea, and hepatotoxicity. Regular monitoring of blood counts and liver function is essential.
-
When are the core patent expiries for Kisqali expected in major markets? Core patents for Kisqali are generally anticipated to expire in major markets such as the United States and Europe between 2027 and 2029.
-
What is the estimated annual cost of Kisqali therapy in the U.S.? The estimated annual treatment cost for Kisqali in the U.S. typically ranges from $120,000 to $144,000 per patient, excluding any applicable discounts or rebates.
Citations
[1] Novartis AG. (2024). Novartis Full Year Results 2023. https://www.novartis.com/sites/default/files/2024-01-31-novartis-q4-2023-results-en.pdf
[2] F Grace, K. A. (2023). Ribociclib in Combination with Endocrine Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer: A Review of the MONALEESA Trials. Breast Cancer: Targets and Therapy, 15, 317-330. doi:10.2147/BCTT.S368680
[3] U.S. Food and Drug Administration. (n.d.). Drug Approval Package: Kisqali (ribociclib). Retrieved from FDA databases.
[4] European Medicines Agency. (2018). Summary of Product Characteristics: Kisqali.
[5] U.S. Food and Drug Administration. (2023, November 17). FDA Approves New Indication for Kisqali (ribociclib) Plus Endocrine Therapy for Advanced or Metastatic HR+/HER2- Breast Cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-indication-kisqali-ribociclib-plus-endocrine-therapy-advanced-or-metastatic-hrher2
[6] Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Delaloge, S., Abrance, P. M., Hurvitz, S. A., ... & Im, S. A. (2018). Overall Survival Results from the MONALEESA-2 Study: Ribociclib and Letrozole in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. The New England Journal of Medicine, 378(10), 947-957. doi:10.1056/NEJMoa1709715
[7] Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Im, Y. H., Hegg, R., ... & Fence, V. (2019). Overall Survival with Ribociclib plus Fulvestrant in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer in the MONALEESA-3 Study. Journal of Clinical Oncology, 37(24), 2182-2191. doi:10.1200/JCO.2018.79.4159
[8] Johnston, S. R., Hegg, R., Im, S. A., Green, M. O., Delaloge, S., Curigliano, G., ... & Fence, V. (2020). Post-Tamoxifen Ribociclib Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: The MONALEESA-3 Randomized Trial. Journal of Clinical Oncology, 38(1), 19-28. doi:10.1200/JCO.2019.81.9127
[9] Healthcare Bluebook. (n.d.). Kisqali Prices, Coupons, and Patient Assistance Programs. Retrieved from healthcarebluebook.com (Note: Specific pricing data is dynamic and requires consultation with healthcare pricing databases for real-time figures).
More… ↓
